Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
https://doi.org/10.21518/2079-701X-2018-19-68-72
Abstract
The article describes a clinical case of ALK-positive non-small cell lung cancer and its long-term treatment with a chemotherapy drug pemetrexed as first-line regimen followed by pemetrexed maintenance therapy.
About the Authors
A. M. Lozhkina
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
M. A. Sviridenko
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
A. O. Cheremnykh
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
E. A. Filippova
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
M. A. Urtenova
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
S. V. Odintsova
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
S. V. Orlov
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation, St.Petersburg
Russian Federation
Russian Federation
References
1. World Health Organization: Intrnational Agency for Research on Cancer. GLOBOCAN 2012:Estimated cancer incidence, mortality and prevalence worldwide in 2012 (2012). http:// globocan.iarc.fr.
2. Didkowska J, Wojciechowska U, Mańczuk M, Łobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med, 2016 Apr, 4(8): 150.
3. Practical recommendations RUSSCO, version 2017: 34.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003, 21: 2636–2644.
5. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22: 1589– 1597.
6. Scagliotti G, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patientswith advanced-stage NSCLC. J Clin Oncol, 2008, 26: 3543–3551.
7. hih C, Chen VJ, Gossetti LS et al. LY231514, a pirrolo[2,3-d]pyrimidine-based antifolate that inhibitsmultiple folate requiring enzymes. Cancer Res, 1997, 57: 1116–1123.
8. Shaw, AT, Varghese, AM, Solomon, BJ et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol, August 10, 2012 [Epub ahead of print].
9. Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung et al. Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. Onco Targets Ther, 2016, 9: 1579–1587.
10. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol., 2004, 22(9): 1589–1597.
11. Gridelli C, Kaukel E, Gregorc V et al. Singleagent pemetrexed or sequential pemetrexed/ gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinumbased chemotherapy: amulticenter, randomized, phase II trial. J Thorac Oncol, 2007, 2: 221–229.
12. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist, 2010, 15(12): 1352–1358.
13. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res, 2011, 17: 2081.
14. Jo J, Kim SH, Kim YJ, Lee J et al. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Yonsei Med J, 2018 Mar, 59(2): 202-210. doi: 10.3349/ymj.2018.59.2.202.
15. Solomon BJ, Mok T, Kim D-W et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. The New England Journal of Medicine. Massachusetts Medical Societ, 2014 Dec 4.
16. Bearz A, Garassino I, Tiseo M et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer, 2010, 8: e3–e5.
Review
For citations:
Lozhkina AM, Sviridenko MA, Cheremnykh AO, Filippova EA, Urtenova MA, Odintsova SV, Orlov SV. Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +). Meditsinskiy sovet = Medical Council. 2018;(19):68-72. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-68-72
Views:
653
Email this article 